Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

FAP-α-Responsive Size-Transformable Lipid Nanoparticles for Stromal Remodeling and Enhanced Drug Penetration in Fibrotic Hepatocellular Carcinoma.

ACS applied materials & interfaces·2026
Same author

Spatiotemporally programmed nanomedicine engineering to resolve conflicting immunosignals in triple-negative breast cancer.

Signal transduction and targeted therapy·2026
Same author

Associations of Dietary Patterns and Dietary Index with Iron Deficiency Across Different Stages Among Children Aged 9-17 Years in Guangzhou, China: A Cross-Sectional Study.

Nutrients·2026
Same author

A critical analysis on ENaC inhibitors, unravelling molecular medicinal insights and promising research roadmap in the treatment of cystic fibrosis.

European journal of medicinal chemistry·2026
Same author

Recyclable standardized sludge for performance evaluation of low-temperature drying units: Preparation and feasibility verification.

Journal of environmental management·2026
Same author

Joint association of atherogenic index of plasma (AIP) and body roundness index (BRI) with cardiometabolic multimorbidity in adults in Guangzhou, China.

Cardiovascular diabetology·2026
Same journal

Targeting the GLP-1 receptor pathways for dual management of obesity and depression.

Drug discovery today·2026
Same journal

Chemical intervention strategies targeting MYC for cancer therapy.

Drug discovery today·2026
Same journal

How many protein pairs can we chemically target?

Drug discovery today·2026
Same journal

From trial-and-error to inverse design: how AI is redefining drug delivery systems.

Drug discovery today·2026
Same journal

Critical evaluation of the key mediators causing life-threatening symptoms during human anaphylaxis.

Drug discovery today·2026
Same journal

A20 as a novel immunoregulatory target for neuroinflammation.

Drug discovery today·2026
See all related articles

Related Experiment Video

Updated: Jul 13, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.6K

Advances in developing noncovalent small molecules targeting Keap1.

Marilia Barreca1, Yuting Qin2, Marie Elodie Hélène Cadot2

  • 1Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100 Copenhagen, Denmark; Department of Biological, Chemical and Pharmaceutical Sciences and Technologies (STEBICEF), University of Palermo, Via Archirafi 32, 90123 Palermo, Italy.

Drug Discovery Today
|October 18, 2023
PubMed
Summary
This summary is machine-generated.

Targeting Kelch-like ECH-associated protein 1 (Keap1) with noncovalent inhibitors offers a promising therapeutic strategy for oxidative stress and inflammation. These compounds modulate nuclear factor erythroid 2-related factor 2 (Nrf2) pathways, presenting an alternative to existing covalent drugs.

More Related Videos

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

843
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

Related Experiment Videos

Last Updated: Jul 13, 2025

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA
10:21

Author Spotlight: Streamlining Protein Target Prediction and Validation via Molecular Docking and CETSA

Published on: February 23, 2024

2.6K
Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
05:28

Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites

Published on: June 2, 2023

843
High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.7K

Area of Science:

  • Pharmacology and Drug Discovery
  • Molecular Biology
  • Biochemistry

Background:

  • Kelch-like ECH-associated protein 1 (Keap1) is a critical drug target for conditions characterized by oxidative stress and inflammation.
  • Current therapeutic strategies include three approved covalent Keap1-binding drugs.
  • Noncovalent inhibitors targeting the Keap1-Nrf2 interaction present a viable alternative with distinct pharmacological profiles.

Purpose of the Study:

  • To explore the opportunities and challenges associated with targeting Keap1 using both covalent and noncovalent inhibitors.
  • To provide a comprehensive review of existing noncovalent Keap1-Nrf2 inhibitors.
  • To evaluate the therapeutic potential of noncovalent inhibitors by examining their pharmacological effects.

Main Methods:

  • Literature review and analysis of existing covalent and noncovalent Keap1 inhibitors.
  • Comparative assessment of the off-target profiles and pharmacodynamic effects of different inhibitor types.
  • Focus on the pharmacological mechanisms and therapeutic implications of noncovalent Keap1-Nrf2 inhibitors.

Main Results:

  • Both covalent and noncovalent inhibitors prevent the degradation of nuclear factor erythroid 2-related factor 2 (Nrf2), inducing antioxidant and anti-inflammatory responses.
  • Significant differences exist in the off-target profiles and precise pharmacodynamic outcomes between covalent and noncovalent drug classes.
  • Noncovalent inhibitors demonstrate considerable therapeutic potential, warranting further investigation.

Conclusions:

  • Noncovalent Keap1-Nrf2 inhibitors offer a promising therapeutic avenue with distinct advantages over covalent agents.
  • Understanding the nuanced pharmacological effects and off-target profiles is crucial for optimizing noncovalent inhibitor development.
  • Further research into noncovalent inhibitors is essential to fully realize their therapeutic potential in treating diseases related to oxidative stress and inflammation.